Your browser doesn't support javascript.
loading
Multivalent Aptamer-Based Lysosome-Targeting Chimeras (LYTACs) Platform for Mono- or Dual-Targeted Proteins Degradation on Cell Surface.
Duan, Qiao; Jia, Hao-Ran; Chen, Weichang; Qin, Chunhong; Zhang, Kejing; Jia, Fei; Fu, Ting; Wei, Yong; Fan, Mengyang; Wu, Qin; Tan, Weihong.
Affiliation
  • Duan Q; Institute of Molecular Medicine (IMM), Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University, Shanghai, 200120, China.
  • Jia HR; Institute of Molecular Medicine (IMM), Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University, Shanghai, 200120, China.
  • Chen W; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
  • Qin C; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
  • Zhang K; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
  • Jia F; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
  • Fu T; Department of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410006, China.
  • Wei Y; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
  • Fan M; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
  • Wu Q; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
  • Tan W; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Adv Sci (Weinh) ; 11(17): e2308924, 2024 May.
Article in En | MEDLINE | ID: mdl-38425146
ABSTRACT
Selective protein degradation platforms have opened novel avenues in therapeutic development and biological inquiry. Antibody-based lysosome-targeting chimeras (LYTACs) have emerged as a promising technology that extends the scope of targeted protein degradation to extracellular targets. Aptamers offer an advantageous alternative owing to their potential for modification and manipulation toward a multivalent state. In this study, a chemically engineered platform of multivalent aptamer-based LYTACs (AptLYTACs) is established for the targeted degradation of either single or dual protein targets. Leveraging the biotin-streptavidin system as a molecular scaffold, this investigation reveals that trivalently mono-targeted AptLYTACs demonstrate optimum efficiency in degrading membrane proteins. The development of this multivalent AptLYTACs platform provides a principle of concept for mono-/dual-targets degradation, expanding the possibilities of targeted protein degradation.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Aptamers, Nucleotide / Proteolysis / Lysosomes Limits: Humans Language: En Journal: Adv Sci (Weinh) / Advanced science (Weinheim) Year: 2024 Document type: Article Affiliation country: China Country of publication: Alemania

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Aptamers, Nucleotide / Proteolysis / Lysosomes Limits: Humans Language: En Journal: Adv Sci (Weinh) / Advanced science (Weinheim) Year: 2024 Document type: Article Affiliation country: China Country of publication: Alemania